- AU$55.38bn
- AU$72.46bn
- $15.56bn
CSL slips to over 9-year low on annual forecast downgrade, potential $5 billion impairments
Australia's CSL tanks on trimming annual forecasts, flagging $5 billion impairments
Australia’s CSL cuts 2026 profit and revenue outlook, flags impairments (updated)
Brief: CSL Expects FY26 Revenue $15.2 Bln, NPATA $3.1 Bln At Constant Currency
Australia's CSL cuts 2026 earnings forecast as payoff from growth initiatives delayed
Factbox: Global drugmakers rush to boost US presence as tariff threat looms
Australia's CSL falls to over 8-yr low as Pentagon ends flu vaccine mandate
Australian healthcare stocks hit 8-year low as CSL extends vaccine rout
Australia's CSL hits 9-year low after US scraps mandatory flu vaccines for military
Australia's CSL knocked by Pentagon flu policy shift, stock sinks to 2017 low
Australian superannuation fund HESTA names ESSSuper chief Robbie Campo as next CEO
Jefferies trims CSL's PT as growth in key markets falls short of 'stellar'
Australia's CSL gains on US tariff relief on key product imports
Brief: CSL Notes Announcement By United States Administration On 2 April
CSL flags global stockout of bleeding disorder gene therapy
Brief: CSL Currently Experiencing Temporary Global Stockout Of HEMGENIX
Brief: Csl Seqirus Signs Agreement With Pan American Health Organization
Factbox: Global drugmakers rush to boost US presence as tariff threat looms
Brief: CSL Announces Expansion Of Illinois Plasma Therapy Manufacturing Facility